Loading
A phase 3 trial of Cadonilimab in gastric & gastro-oesophageal junction cancer, run by Akeso, now recruiting.
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma is a phase 3 interventional study registered as NCT07023315 by Akeso, with 760 participants planned, started 2025-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Cadonilimab, SOX chemotherapy and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/